Suven Life Sciences, a Hyderabad-based biopharmaceutical company, has received two product patents in Mexico and Korea for two of its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The patents are valid upto 2023.
“Suven's drug candidates, for which these patents are issued, are being developed for CNS (central nervous system) disorders. These candidates target an $18 million (approximately Rs 72 crore) potential market opportunity globally,” Venkat Jasti, chief executive officer of Suven,
stated in a press release on Monday.
These granted patents are exclusive intellectual property of Suven and are achieved through the exclusive internal discovery research efforts.
Products out of these inventories, which are at present in pre-clinical development, may be out-licensed at the stage of clinical phase-I or phase-II stage, the release added.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like attention deficient hyperactivity, Alzheimer’s, Parkinson, schizophrenia, and Huntington's.
Suven Life has six internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's, Parkinson's and obesity.
So far, Suven has filed nearly 29 product patent applications through the Patent Cooperation Treaty (PCT), covering more than 145 countries. Of these, 5 product patents are granted in various countries.
No comments:
Post a Comment